Cardiovascular magnetic resonance imaging patterns of acute COVID-19 mRNA vaccine-associated myocarditis in young male patients: A first single-center experience

Ruben Evertz; Alexander Schulz; Torben Lange; Sören J Backhaus; Dirk Vollmann; Johannes T Kowallick; Stephan von Haehling; Gerd Hasenfuß; Andreas Schuster

doi:10.3389/fcvm.2022.965512

Cardiovascular magnetic resonance imaging patterns of acute COVID-19 mRNA vaccine-associated myocarditis in young male patients: A first single-center experience

Front Cardiovasc Med. 2022 Aug 23:9:965512. doi: 10.3389/fcvm.2022.965512. eCollection 2022.

Authors

Ruben Evertz^{1

2}, Alexander Schulz^{1

2}, Torben Lange^{1

2}, Sören J Backhaus^{1

2}, Dirk Vollmann³, Johannes T Kowallick^{2

4}, Stephan von Haehling^{1

2}, Gerd Hasenfuß^{1

2}, Andreas Schuster^{1

2}

Affiliations

¹ Department of Cardiology and Pneumology, University Medical Center Göttingen (UMG), Göttingen, Germany.
² German Center for Cardiovascular Research (DZHK), Göttingen, Germany.
³ Herz- and Gefäßzentrum Göttingen, Göttingen, Germany.
⁴ Institute for Diagnostic and Interventional Radiology, University Medical Center Göttingen (UMG), Göttingen, Germany.

Abstract

Background: The risk of myocarditis after mRNA vaccination against COVID-19 has emerged recently. Current evidence suggests that young male patients are predominantly affected. In the majority of the cases, only mild symptoms were observed. However, little is known about cardiac magnetic resonance (CMR) imaging patterns in mRNA-related myocarditis and their differences when compared to classical viral myocarditis in the acute phase of inflammation.

Methods and results: In total, 10 mRNA vaccination-associated patients with myocarditis were retrospectively enrolled in this study and compared to 10 patients suffering from viral myocarditis, who were matched for age, sex, comorbidities, and laboratory markers. All patients (n = 20) were hospitalized and underwent a standardized clinical examination, as well as an echocardiography and a CMR. Both, clinical and imaging findings and, in particular, functional and volumetric CMR assessments, as well as detailed tissue characterization using late gadolinium enhancement and T1 + T2-weighted sequences, were compared between both groups. The median age of the overall cohort was 26 years (group 1: 25.5; group 2: 27.5; p = 0.57). All patients described chest pain as the leading reason for their initial presentation. CMR volumetric and functional parameters did not differ significantly between both groups. In all cases, the lateral left ventricular wall showed late gadolinium enhancement without significant differences in terms of the localization or in-depth tissue characterization (late gadolinium enhancement [LGE] enlargement: group 1: 5.4%; group 2: 6.5%; p = 0.14; T2 global/maximum value: group 1: 38.9/52 ms; group 2: 37.8/54.5 ms; p = 0.79 and p = 0.80).

Conclusion: This study yielded the first evidence that COVID-19 mRNA vaccine-associated myocarditis does not show specific CMR patterns during the very acute stage in the most affected patient group of young male patients. The observed imaging markers were closely related to regular viral myocarditis in our cohort. Additionally, we could not find any markers implying adverse outcomes in this relatively little number of patients; however, this has to be confirmed by future studies that will include larger sample sizes.

Keywords: COVID-19; cardiac magnetic resonance; mRNA-related; myocarditis; vaccination.